良性(世界卫生组织I级)海绵窦脑膜瘤的立体定向放射外科治疗——国际立体定向放射外科协会(ISRS)实践指南:一项系统综述
本指南由国际立体定向放射外科协会基于1963年1月至2014年12月的系统综述制定,纳入49篇回顾性研究。海绵窦脑膜瘤立体定向放射外科治疗后5年无进展生存率为86%至99%,10年为69%至97%,神经功能保留率为80%至100%。证据级别为III级,立体定向放射外科具有有利的获益风险比。
要点
- 5年无进展生存率为86%至99%,10年为69%至97%。
- 立体定向放射外科后神经功能保留率为80%至100%。
- 证据限于III级,所有研究均为回顾性。
核心结论
- 文献限于III级证据,基于观察结果,立体定向放射外科为海绵窦脑膜瘤患者提供了有利的获益风险比。
研究设计与样本
- 国际立体定向放射外科协会系统综述,检索1963年1月至2014年12月PubMed、EMBASE和Cochrane对照试验中心注册库,纳入英文、每组至少10例患者的文献,共筛选569篇摘要后纳入49篇全文文章。
主要发现
- 所有研究均为回顾性,多数报告结局良好,5年无进展生存率为86%至99%,10年无进展生存率为69%至97%。
- 立体定向放射外科后神经功能保留率为80%至100%。
关键数值与推荐
- 对于直径大于3 cm且有症状的海绵窦脑膜瘤,若患者愿意接受且医学上适合开放手术,可考虑切除。
- 对于残留或复发肿瘤,可根据肿瘤体积和与邻近危及器官的临近程度等因素,采用辅助或挽救性立体定向放射外科治疗。
临床怎么用
- 对于直径大于3 cm且有症状的海绵窦脑膜瘤,若患者愿意接受且医学上适合开放手术,可考虑切除。
- 对于残留或复发肿瘤,可根据肿瘤体积和与邻近危及器官的临近程度等因素,采用辅助或挽救性立体定向放射外科治疗。
局限性
- 文献限于III级证据。
- 所有研究均为回顾性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiosurgery (SRS) has become popular as a standard treatment for cavernous sinus (CS) meningiomas. OBJECTIVE: To summarize the published literature specific to the treatment of CS meningioma with SRS found through a systematic review, and to create recommendations on behalf of the International Stereotactic Radiosurgery Society. METHODS: Articles published from January 1963 to December 2014 were systemically reviewed. Three electronic databases, PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials, were searched. Publications in English with at least 10 patients (each arm) were included. RESULTS: Of 569 screened abstracts, a total of 49 full-text articles were included in the analysis. All studies were retrospective. Most of the reports had favorable outcomes with 5-yr progression-free survival (PFS) rates ranging from 86% to 99%, and 10-yr PFS rates ranging from 69% to 97%. The post-SRS neurological preservation rate ranged from 80% to 100%. Resection can be considered for the treatment of larger (>3 cm in diameter) and symptomatic CS meningioma in patients both receptive to and medically eligible for open surgery. Adjuvant or salvage SRS for residual or recurrent tumor can be utilized depending on factors such as tumor volume and proximity to adjacent critical organs at risk. CONCLUSION: The literature is limited to level III evidence with respect to outcomes of SRS in patients with CS meningioma. Based on the observed results, SRS offers a favorable benefit to risk profile for patients with CS meningioma.
引用
- Lee CC, Trifiletti DM, Sahgal A, et al. Stereotactic Radiosurgery for Benign (World Health Organization Grade I) Cavernous Sinus Meningiomas-International Stereotactic Radiosurgery Society (ISRS) Practice Guideline: A Systematic Review. Neurosurgery. 2018. PMID: 29554317. doi:10.1093/neuros/nyy009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。